I will just add this footnote to your timeline thoughts: If you are part of the 85% who have been sentenced with the MSS CRC for which current regimens are not touching you would have strong incentive to participate in this trial. I expect unlike Leronlimab in severe/critical COVID where remdesivir was taking up all the treatment oxygen and enrollment was like watching paint dry, we may find patients enroll fairly quickly.

“Start screening in 2025. That's not enrollment, although enrollment and dosing should soon follow. One of my mantras: Oncology is tough.”

You are right in pointing out enrollment should soon follow, but it is usually quickly after screening and informed consent. This is not like a jury trial where you screen for a pool of jurors and then have a trial; as providers (and their study support staff) find qualifying patients they typically are enrolled promptly following consent.